Proactive Investors - Run By Investors For Investors

Helius Medical gets Canadian boost with three new clinics authorized to use brain device

The Portable Neuromodulation Stimulator is a noninvasive medical device to treat chronic balance issues stemming from traumatic brain injury
Finger pointing to brain
The Portable Neuromodulation Stimulator is a noninvasive medical device to treat chronic balance issues from brain injury

Helius Medial Technologies Inc (TSE:HSM) (NASDAQ:HSDT) got a major boost on Wednesday after the neurotech company announced that its Portable Neuromodulation Stimulator device is now available in three Canadian clinics.

The Portable Neuromodulation Stimulator (PoNS) is a noninvasive medical device to treat chronic balance issues stemming from traumatic brain injury. The prescription-only product is used in conjunction with a physical therapy regimen.

Shares of Helius soared in both the US and Canada, up 13.5% in New York to US$3.20 and 15.3% in Toronto at C$4.37.

READ: LexaGene hits major milestone, places its pathogen-detecting technology in major Massachusetts veterinary hospital

Pennsylvania-based Helius opened its first authorized clinic in the province of Quebec in December 2018 and the second in February of this year in British Columbia. In addition to the two existing clinics, Helius now adds two Ontario and one Alberta-based location.

“We are pleased that the strategy to accelerate expansion plans in Canada has driven the further development of the clinic system authorized to provide PoNS Treatment,” said Philippe Deschamps, CEO of Helius in a statement. 

“Patients who have had mild-to-moderate traumatic brain injuries are often not able to travel long distances and now, with a presence in Montreal, Vancouver, Toronto, Calgary and Ottawa, over 50% of Canadians will have direct local access to PoNS Treatment.”

The PoNS is an investigational medical device in the United States, the European Union, and Australia and is not currently commercially available outside of Canada.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

View full HSM profile View Profile

Helius Medical Technologies Timeline

Related Articles

microscope
April 30 2019
The health sciences company has five research and development programs, including gene therapy, its Sol-gel program for nose-to-brain delivery of medical compounds including cannabinoids, as well as non-addictive analgesic peptides as a replacement for morphine, fentanyl and oxycodone
pills
April 12 2019
The biotechnology company is developing a platform of unique drugs designed to prevent serious gastrointestinal damage and bleeding caused by chronic naproxen use
LX2 analyzer
May 07 2019
Armed with promising study results and proven technology, LexaGene is getting ready to launch the LX2 Genetic Analyzer to underserved markets valued at an estimated US$40 billion
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use